Asymptomatic C diff Associated With Pathogen Reservoir, Affecting Carriers, Patients, Employees in ICU
Genomically-confirmed assessments of the risk for CDI found that asymptomatic carriers serve as viral reservoirs in clinical settings.
Nosocomial Infections
Legionnaires’ Disease-Associated Hospitalizations Spiked Between 2006 and 2010
Research results underscore the importance of understanding the characteristics of Legionnaires’ disease and the need for early diagnosis.
GII.4 Genotype Most Common in Sporadic Pediatric Acute Gastroenteritis
Children with GII.4 type norovirus had more severe symptoms and required more medical care.
Guideline Update: Revised Consensus for Vancomycin Dosing and Monitoring in Serious MRSA Infection
Four medical societies have come together to publish an updated consensus guideline on dosing and monitoring vancomycin for the treatment of serious MRSA infections.
Mylan Recalls One Lot of Daptomycin for Injection
According to Mylan, the administration of the recalled product may lead to “serious adverse events including, but not limited to, local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.”
Methotrexate-Induced Acute Kidney Injuries in Patients with Hematologic Malignancies
Upon starting methotrexate treatment, LDH and albumin levels may be signals for AKIs in patients with hematologic malignancies.
Study Finds Vancomycin Increased Risk for Cytomegalovirus Reactivation After Hematopoietic Cell Transplant
A retrospective study of CMV-seropositive adults receiving allogeneic HCT and CMV-seronegative HLA-matched sibling donors found that vancomycin exposure before HCT increased the risk for CMV reactivation.
Bezlotoxumab Effective for Reducing Clostridioides difficile Recurrence
A post hoc analysis was conducted to assess the efficacy of bezlotoxumab in a subgroup of participants from the MODIFY I and II trials.
Strategies for Safe Home-Based Outpatient Parenteral Antimicrobial Therapy
An interactive, in-person barrier identification and mitigation tool can ensure safe administration of home-based outpatient parenteral antimicrobial therapy.
Recarbrio Noninferior to Pip/Tazo for Hospital-Acquired, Ventilator-Associated Bacterial Pneumonia
Merck announced results from the phase 3 RESTORE-IMI 2 trial of imipenem/relebactam/cilastatin (Recarbrio™) for the treatment of adults with hospital-acquired or ventilator-associated bacterial pneumonia (HABP/VABP).
-
Loading...
-
Loading...
Next post in Respiratory
